Japanese encephalitis
Pathogen
Flaviviridae, flavivirus, enveloped, ssRNA
Epidemiology
Main vector is Culex
Pig, amplifier of virus. natural infection rate of 90-100%, high-titre viraemia lasts for 2-4 days
Human/horse: low-level and short-lived viraemia
Clinical features
incubation period 6-8 days
most asymptomatic or mild signs (1/200 - 1/2,000)
children and eldery at highest risk for severe disease
elderly: high CFR (30%)
Headache, high fever, stiff neck, stupor... paralysis, seizures, convulsions, coma
Abortion of fetus
Neuropsychiatric sequelae (30-50% of survivors)
Diagnosis
Clinical signs...
Virus isolation: CSF sample, brain
Nucleic acid: RT-PCR (but viraemia finished when encephalitis started)
Antibody (HI, IFA, CF, ELISA): IgM in serum or CSF
Treatment
No specific treatment, supportive
Prevention
Vector control
Personal protection measures
Vaccination: equine & human
Live attenuated vaccine (SA-14-14-2), mainly used for equine and swine. Inactivated vaccine (JE-VAX) most commonly used for humans/travelers
History
1870's "Summer encephalitis" epidemics
1924: great epidemic in Japan (6,125 cases, >3,000 deaths)
1934 first isolated (from fatal human encephalitis)
1935 isolated from Culex tritaeniorhynchus, 1940-1978 epidemics in Japan, China, Korea, India
Vaccine developed in the 1950's, mass immunisation and cases decreased. Also lifestyle change with increased use of air-conditioning and agriculture developments in the 1960's